Hyperfine has enrolled the first subjects in the PRISM PMR trial, which aims to assess the application of the Swoop portable magnetic resonance imaging (MRI) system within the operating room (OR), during neurosurgical procedures.
This initiative is part of the company’s efforts to expand the use of brain MRI technology across various healthcare settings.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study is designed to gather data to enhance the system’s clinical utility in the OR.
It will assess Swoop’s capability to detect post-surgical complications such as bleeding or stroke and its potential to be integrated into surgical workflows, possibly reducing hospital stays and expediting recovery.
Overseeing the three-month study at the Atlas Surgery Center in New York, US, is neurosurgeon and principal investigator Dr Elad Levy.
Hyperfine CEO and president Maria Sainz said: “Having a high-field MRI right in the OR is not practical. The PRISM PMR study and Dr Levy’s pioneering work illustrates how the Swoop system can potentially reshape neurosurgical care, bringing valuable clinical insights and workflow benefits.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“By enabling neurosurgeons to obtain critical imaging immediately before and after a procedure, the Swoop system can help improve patient safety, reduce costs, and transform how surgical centres think about imaging infrastructure.”
The Swoop systems are cleared by the US Food and Drug Administration (FDA) for brain imaging in patients of all ages.
These devices are designed to use ultra-low-field MRI to generate images of the head’s internal structures when a full diagnostic examination is not possible. When interpreted by a trained physician, these images can assist in diagnosis.
Dr Levy said: “Portable brain MRI allows us to confirm results, rule out major complications, and potentially safely discharge patients on the same day. This technology has the potential to redefine surgical workflows and change how we care for patients.
“It’s also helping us eliminate bottlenecks by shifting appropriate patients to the ambulatory setting, which in turn frees up valuable surgical capacity in the hospital.”
In March 2025, Hyperfine announced a collaboration with NVIDIA to improve the AI capabilities of the Swoop portable MRI system.
